Abeona Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $330.0M
- Price
- $6.09
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.18%
- Volume
- 894.8K
About
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Quick stats
Shares outstanding54.2M
Computed float47.4M
Float / shares87.4%
Cash runway (months)21.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000318306
AI Summary
AI-generated1/19
majorbullishearnings
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
Abeona reported Q2 revenue of $11.4 million, a 31% increase from the prior quarter, driven by the treatment of five patients with ZEVASKYN.
Commercial execution advanced with the activation of new Qualified Treatment Centers and the securing of CMS NTAP status to facilitate Medicare reimbursement starting October 1.
The company ended the quarter with $146.8 million in cash and short-term investments, down from $191.4 million at year-end, while R&D expenses decreased significantly to $5.0 million.
Red flags
- Revenue not recognized for two patients due to manufacturing yield issues or lot release specifications
- Cash position declined from $191.4 million to $146.8 million during the first six months of 2026